Our studies using clinical samples support that upregulation of ODF2L in primary EOC cells positively correlates with CDK1 inactivation and cell viability in vitro and predicts xenografted tumor growth in vivo under AZD1775 treatment. This evidence concerns the gene CDK1 and neoplasm.